单药来那度胺治疗复发/难治性套细胞淋巴瘤的II期研究长期分析
本文报告了3项多中心II期研究(NHL-002、NHL-003及MCL-001)中单药来那度胺治疗复发/难治性套细胞淋巴瘤(MCL)的长期随访结果。206例复发MCL患者接受来那度胺25 mg/日口服(每28天周期第1-21天),中位随访时间分别为6.8、7.6和52.2个月。合并最佳总缓解率为33%(含11%完全缓解/未经确认的完全缓解),中位缓解时间2.2个月,中位缓解持续时间16.6个月(95%CI:11.1%-29.8%)。
要点
- 单药来那度胺在复发/难治性MCL中合并最佳总缓解率为33%,含11%完全缓解/未经确认的完全缓解。
- 中位缓解时间2.2个月,中位缓解持续时间16.6个月(95%CI:11.1%-29.8%)。
- 骨髓抑制是最常见不良事件,安全性特征一致且可控。
核心结论
- 单药来那度胺在多项II期研究中,对重度经治的复发/难治性MCL患者(包括既往接受硼替佐米治疗者)显示出一致的疗效和安全性。
研究设计与样本
- 基于3项多中心II期研究(2项纳入复发/难治性侵袭性非霍奇金淋巴瘤,1项聚焦硼替佐米治疗后MCL)的长期随访分析。
- 共206例复发MCL患者接受单药来那度胺25 mg/日口服,每28天周期第1-21天给药。
- 中位年龄67岁(63%≥65岁),91%为III/IV期疾病,50%既往接受≥4线治疗方案。
- 随访时间分别为6.8个月(NHL-002)、7.6个月(NHL-003)和52.2个月(MCL-001)。
主要发现
- 合并最佳总缓解率为33%,其中11%为完全缓解/未经确认的完全缓解。
- 中位缓解时间2.2个月,中位缓解持续时间16.6个月(95%CI:11.1%-29.8%)。
- 骨髓抑制为最常见不良事件,安全性特征一致且可控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post-bortezomib). The purpose of this report is to provide longer follow-up on the MCL-001 study (follow-ups were 6.8 [NHL-002], 7.6 [NHL-003], and 52.2 [MCL-001] months). The 206 relapsed MCL patients treated with single-agent lenalidomide (25 mg/day PO, days 1 to 21 every 28-days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow-up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%-29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single-agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib.
引用
- Witzig TE, Luigi Zinzani P, Habermann TM, et al. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017. PMID: 28699256. doi:10.1002/ajh.24854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。